PharmaEngine, Inc. (TPEX:4162)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
57.00
+0.10 (0.18%)
At close: Mar 24, 2026

PharmaEngine Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
8,17510,11512,97415,15817,96110,207
Market Cap Growth
-50.52%-22.04%-14.41%-15.60%75.96%21.08%
Enterprise Value
3,5015,5279,24111,61914,3486,496
Last Close Price
56.9070.4083.3595.67110.5762.24
PE Ratio
21.1526.097.4155.1956.3423.96
Forward PE
20.6226.0010.9142.71150.6038.52
PS Ratio
8.9711.105.1419.7527.4515.59
PB Ratio
1.662.052.403.924.642.59
P/TBV Ratio
1.662.052.403.934.642.59
P/FCF Ratio
4.735.8628.4659.0890.4510.98
P/OCF Ratio
4.735.8628.4158.9988.9110.98
EV/Sales Ratio
3.846.063.6615.1421.939.92
EV/EBITDA Ratio
8.0412.694.5041.7150.6217.88
EV/EBIT Ratio
8.2312.994.5041.9250.7517.91
EV/FCF Ratio
2.033.2020.2745.2972.266.99
Debt / Equity Ratio
0.010.010.000.000.010.00
Debt / EBITDA Ratio
0.100.100.000.050.080.02
Debt / FCF Ratio
0.020.020.020.060.110.01
Net Debt / Equity Ratio
-0.95-0.95-0.71-0.93-0.94-0.97
Net Debt / EBITDA Ratio
-10.73-10.73-1.87-12.97-12.84-10.47
Net Debt / FCF Ratio
-2.71-2.71-8.45-14.08-18.33-4.09
Asset Turnover
0.170.170.520.190.160.16
Inventory Turnover
1.521.522.161.942.502.46
Quick Ratio
26.9026.9013.0746.5049.3445.57
Current Ratio
27.1727.1713.1546.7849.8645.71
Return on Equity (ROE)
7.51%7.51%37.81%7.10%8.16%10.72%
Return on Assets (ROA)
4.84%4.84%26.18%4.37%4.42%5.51%
Return on Invested Capital (ROIC)
141.49%36.04%185.11%93.31%125.60%73.39%
Return on Capital Employed (ROCE)
8.60%8.60%38.00%7.20%7.30%9.20%
Earnings Yield
4.74%3.83%13.50%1.81%1.77%4.17%
FCF Yield
21.12%17.07%3.51%1.69%1.11%9.11%
Dividend Yield
10.54%-7.20%1.57%1.81%4.34%
Payout Ratio
222.35%222.35%12.30%104.57%121.62%85.44%
Buyback Yield / Dilution
-0.12%-0.12%-0.13%-0.03%0.72%0.80%
Total Shareholder Return
10.19%-0.12%7.07%1.54%2.53%5.13%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.